@FierceBiotech: Check out this week's roundup of job changes in biopharma via @MichaelGFierce and @EmilyMFierce. Report | Follow @FierceBiotech
@JohnCFierce: Aveo shares shellacked after Astellas drops EU game plan on kidney cancer. More | Follow @JohnCFierce
@RyanMFierce: Merck marks another failure in elusive hunt for Parkinson's disease drugs. Article | Follow @RyanMFierce
> Following criticisms about conflicts of interest in its ranks, Novartis ($NVS) said on its website that two company employees were involved in what were supposed to be independent clinical trials for its blockbuster Diovan. Article
> Sangamo BioSciences ($SGMO) has scored a $6.4 million award from the California Institute for Regenerative Medicine to develop a potential corrective therapy based on the biotech's gene-editing technology for the blood disorder beta-thalassemia. Release
> QB3 Institute has struck a partnership to open its fifth life sciences incubator to support startups in the Bay Area, targeting a 24,000-square-foot space in the San Francisco's Dogpatch neighborhood. Article
Pharma News
@FiercePharma: Novo Nordisk figures it could launch Victoza (liraglutide) as obesity treatment by end of 2014. Story | Follow @FiercePharma
@EricPFierce: Yes, J&J has an impressive pipeline, but its extensions of existing drugs could add billions to the top line. Report | Follow @EricPFierce
> BRIC markets turning out to be tougher to mine than expected. More
> Former Carl Icahn proxy brawler Alex Denner joins fight against Vivus board. Story
> Novartis apologizes over Diovan study as probe shows employee involvement in trials. Article
@FierceMedDev: Roche wins FDA approval for novel diabetes diagnostic. More | Follow @FierceMedDev
@MarkHFierce: Looks like Panasonic's bid to attract new investment for its healthcare arm is drawing major interest. Story | Follow @MarkHFierce
@DamianFierce: Intuitive won its first da Vinci lawsuit, dodging $8.5M in damages. Article | Follow @DamianFierce
> Ethicon study asserts safety of medical-grade polycarbonate devices. Story
> Covidien, Kona Medical trumpet new tech at EuroPCR. More
> Covidien's board approves pharma spinoff. Article
And Finally… Are the folks from Genentech getting a head start on packing for the big ASCO meeting? Video